

21 December 2023

Press Release

EFPIA Japan

## **Kasper Bødker Mejlvang appointed new Vice Chair of EFPIA Japan**

TOKYO – 21 December 2023 – European Federation of Pharmaceutical Industries and Associations Japan (EFPIA Japan) announced today that Kasper Bødker Mejlvang (President and Representative Director, Novo Nordisk Pharma Ltd.) has been appointed the new Vice Chair of EFPIA Japan effective 1 January 2024, with terms until March 2025. Takahiko Iwaya (Sanofi K.K.) and Takafumi Horii (AstraZeneca K.K.) remain Chair and Vice Chair, respectively.

“In the coming years, the combination of a larger, elderly population combined with a low birthrate will put immense pressure on the Japanese healthcare system and society at large. New solutions are needed to ensure that patients in Japan get access to new, innovative treatments in a more efficient, flexible, and sustainable healthcare system. EFPIA Japan remains committed to partnering with other stakeholders to find these solutions”, says Kasper Bødker Mejlvang upon the appointment.

### **About EFPIA Japan** (<http://efpia.jp/>)

Established in April 2002, EFPIA Japan represents 23 R&D-based European pharmaceutical companies operating in Japan. In 2022, combined sales from the member companies accounted for roughly 31% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to “Contribute to healthcare and patients in Japan through the early introduction of innovative medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in order to improve Japanese healthcare for all.

### **About EFPIA** (European Federation of Pharmaceutical Industries and Associations) (<http://www.efpia.eu>)

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the biopharmaceutical industry operating in Europe. Through its direct membership of 37 national associations, 40 leading pharmaceutical companies, and a growing number of small and medium-sized enterprises (SMEs), EFPIA’s mission is to create a collaborative environment that enables our members to innovate, discover, develop, and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.

### **Contact:**

Yuko Kidoguchi  
EFPIA Japan Communications Committee  
AstraZeneca K.K.  
Phone: 070-2260-7364  
Email: [yuko.kidoguchi1@astrazeneca.com](mailto:yuko.kidoguchi1@astrazeneca.com)



Kasper Bødker Mejlvang

President and Representative Director  
Novo Nordisk Pharma Ltd.

Kasper Bødker Mejlvang is Senior Vice President in Novo Nordisk A/S and was appointed President and Representative Director of Novo Nordisk Pharma Ltd. In Japan, September 2022.

Prior to his relocation to Japan, Kasper had 20 years of experience in Novo Nordisk across the value chain, 18 of those in senior leadership roles. He started his career in Global HR, then became head of Business Support in manufacturing, followed by three years as Vice President in Research & Development, supporting a major turnaround of CMC Development.

From 2008-2019 Kasper took up several leadership positions in Manufacturing, heading up Insulin API Manufacturing (2008-2010), Product Supply Global Support (2010-2013) and the fill-finish production site in Chartres, France (2013-2018), leading a large turnaround of the site and growing it to more than 1,100 FTE.

From 2019 to 2022, Kasper took the position as General Manager of commercial operations in Novo Nordisk Denmark & Iceland. During this period sales growth increased +20% annually.

Both in his previous and current positions, Kasper has played an active role in the health care system, e.g. as Vice Chair of the Board of Directors of the Danish pharmaceutical trade association (LIF), as well as his current role as Vice Chair of the European Federation of Pharmaceutical Industries and Associations Japan (EFPIA Japan) and as member of the Board of Directors of Danish Chamber of Commerce in Japan.

Kasper was born in 1977 and holds an MSc Management from University of Bath, UK (2002), an MSc in Psychology from University of Copenhagen, DK (2005), and an Executive MBA from IMD in Lausanne, CH (2016).